For the first quarter of the 2027 fiscal year, consolidated net sales were 51,622 million yen (YoY +4.3%), operating income was 4,953 million yen (\u25b329.0% YoY), and net income attributable to owners of the parent was 2,429 million yen (\u25b350.3% YoY). Progress against the medium-term plan Beyond 2027, strengthening of the generic drug business, and the impact of divestment of non-core US operations continued. The full-year plan foresees net sales of 208,400 million yen and operating income of 27,200 million yen.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4887","jir_company_name":"Listed Company Name Saway Group Holdings Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-10","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4887-20260810-01.pdf","jir_short_summary":"For the first quarter of the 2027 fiscal year, consolidated net sales were 51,622 million yen (YoY +4.3%), operating income was 4,953 million yen (\u25b329.0% YoY), and net income attributable to owners of the parent was 2,429 million yen (\u25b350.3% YoY). Progress against the medium-term plan Beyond 2027, strengthening of the generic drug business, and the impact of divestment of non-core US operations continued. The full-year plan foresees net sales of 208,400 million yen and operating income of 27,200 million yen.","jir_summary":"### Performance overview\nAs an IFRS-applying company, quarterly revenue increased, but operating income and net income fell below the prior year. The US business is excluded from continuing operations due to capital relationships, and indicators for continuing and discontinued operations are disclosed separately. Core operating income is an indicator excluding non-recurring factors and decreased YoY. Under the Beyond 2027 medium-term plan, emphasis is placed on stable supply of generic medicines and business sustainability.\n\n### Outlook and capital policy\nThe full-year forecast is net sales of 208,400 million yen, core operating income of 29,600 million yen, operating income of 27,200 million yen, and net income attributable to owners of the parent of 18,600 million yen. While considering the impact of the US non-core asset divestiture, the company will continue to strengthen its generics supply stability and production capacity, advancing the organizational framework through 2027.","jir_financial_highlights":"Sales revenue: 51,622\u767e\u4e07\u5186 (YoY +4.3%)\nOperating income: 4,953\u767e\u4e07\u5186 (YoY \u25b329.0%)\nQuarterly net income attributable to owners of the parent: 2,429\u767e\u4e07\u5186 (YoY \u25b350.3%)\nCore operating income: 6,425\u767e\u4e07\u5186 (YoY \u25b315.4%)\nTotal assets: 368,979\u767e\u4e07\u5186 (increase vs. prior period)","jir_category":"","jir_hashtags":"#SawayGroupHoldings, #Earnings, #Beyond2027, #GenericDrugs","jir_key_figures":"Sales revenue: 51,622\u767e\u4e07\u5186\nOperating income: 4,953\u767e\u4e07\u5186\nNet income attributable to owners of the parent: 2,429\u767e\u4e07\u5186","jir_meta_title":"\u3010Saway Group Holdings\u3011FY2027 Q1 Results\uff5cNet sales 51,622\u767e\u4e07\u5186, Net income 2,429\u767e\u4e07\u5186","jir_meta_description":"Saway Group Holdings FY2027 Q1 results overview. Net sales 51,622\u767e\u4e07\u5186, Operating income 4,953\u767e\u4e07\u5186, Net income attributable to owners of the parent 2,429\u767e\u4e07\u5186. Progress on Beyond2027 and strengthening of the generic drug business.","jir_og_title":"Saway Group Holdings Q1 Results\uff5c51,622\u767e\u4e07\u5186","jir_og_description":"Saway Group Holdings FY2027 Q1 results. Revenue increased, but operating income declined. Progress on the medium-term plan and strengthening of the generic drug business.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":8760,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-100189","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n